优立新治疗急性细菌性感染的临床观察

段明纲; 王其南; 蒋玉富; 郑行萍; 李崇智; 陈海

您当前的位置：

首页 >

文章列表页 >

优立新治疗急性细菌性感染的临床观察

更新时间：2024-01-17

- 优立新治疗急性细菌性感染的临床观察
- A clinical study of Unasyn in the treatment of acute bacterial infections
- 重庆医科大学学报 1997年第2期
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： R978.11
- 纸质出版日期：1997，
扫描看全文
[1]段明纲,王其南,蒋玉富,郑行萍,李崇智,陈海.优立新治疗急性细菌性感染的临床观察[J].重庆医科大学学报,1997(02):105-108.

A clinical study of Unasyn in the treatment of acute bacterial infections[J]. Journal of Chongqing Medical University, 1997,(2).
[1]段明纲,王其南,蒋玉富,郑行萍,李崇智,陈海.优立新治疗急性细菌性感染的临床观察[J].重庆医科大学学报,1997(02):105-108. DOI：

A clinical study of Unasyn in the treatment of acute bacterial infections[J]. Journal of Chongqing Medical University, 1997,(2). DOI：

摘要

优立新与头孢噻肟随机对照治疗呼吸道和泌尿道感染４０例，临床有效率各为１００％和９５％（Ｐ＞０．０５），细菌阴转率各为９４，１％和１００％（Ｐ＞０．０５）。无显著性差异。优立新共治疗３０例，临床有效率和细菌阴转率分别为１００％和９６％。两药副反应均轻微。无因副反应而停药。在优立新治疗病例中，有２例出现皮疹。另２例为肝功能ＡＬＴ和ＡＳＴ暂时性轻度增高。

Abstract

50 hospitalized patients were treated for acute respiratory tract

urinary tract

or other infections. In the randomized trial

there were 20 cases in either Unasyn (sulbactam/ampicillin)or Cefotaxime treatment group. The clinical efficacy rates were 100% for Unasyn and 95% for Cefotaxime(P>0.05)

and the eradication rates of pathogens were 94.1% and 100%

respectively (P>0.05). Unasyn was administered to a total of 30 patients. Tbe clinical efficacy was 100% and the eradication rate of pathogens was 96% .No serious side effects of both drugs Were observed.

关键词

优立新头孢噻肟细菌感染临床评价

Keywords

Unasyn: SulbactamAmpicillinCefotaximeClinical efficacy

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据